Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus CLARITIN D.
CLARITIN REDITABS vs CLARITIN-D
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Seasonal allergic rhinitisPerennial allergic rhinitisIdiopathic chronic urticaria
Temporary relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, runny nose, itchy/watery eyes)Temporary relief of nasal congestion due to common cold, hay fever, or upper respiratory allergies
10 mg orally once daily.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Extensively metabolized in the liver via CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine; undergoes first-pass metabolism.
Loratadine is extensively metabolized in the liver via CYP3A4 and CYP2D6 to its active metabolite descarboethoxyloratadine. Pseudoephedrine is partially metabolized in the liver by N-demethylation and undergoes renal excretion.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Loratadine: 97% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
Loratadine: 97-99% (albumin, alpha-1-acid glycoprotein); desloratadine: 82-87%; pseudoephedrine: negligible (<5%).
Loratadine: 4.5 L/kg. Desloratadine: 90 L/kg. High Vd indicates extensive tissue distribution.
Loratadine: 120 L/kg (extensive tissue distribution); desloratadine: 15-20 L/kg; pseudoephedrine: 2-3 L/kg (distributes into body water).
Orally disintegrating tablet: Bioequivalent to conventional tablets; absolute bioavailability ~100% (extensive first-pass metabolism: 3% parent drug reaches systemic circulation, but active metabolite contributes to effect).
Loratadine: ~40% (high first-pass metabolism); pseudoephedrine: ~100% (oral); desloratadine: ~40-50% (oral).
For GFR <10 mL/min: 10 mg orally every other day. No adjustment needed for GFR ≥10 mL/min.
For GFR 30-50 mL/min: administer every 24 hours. For GFR <30 mL/min: contraindicated due to risk of pseudoephedrine accumulation.
Child-Pugh A: no adjustment. Child-Pugh B or C: 10 mg orally every other day.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: administer every 24 hours or consider alternative therapy.
6 years and older: 10 mg orally once daily. 2-5 years: 5 mg orally once daily (if using oral solution). REDITABS not recommended under 6 years.
Children <12 years: not recommended due to fixed-dose combination. Children ≥12 years: same as adult dose.
Adjust dosing based on renal function; more sensitive to anticholinergic effects; caution in patients over 65 with renal impairment.
Elderly patients (≥65 years): use with caution due to increased sensitivity to pseudoephedrine (e.g., CNS stimulation, hypertension); consider starting with lower dose or alternative therapy.
None
Not available.
["Caution in hepatic impairment; dose adjustment recommended","Caution in severe renal impairment (CrCl <30 mL/min)","May cause drowsiness; avoid driving if affected"]
Severe hypertension or coronary artery disease; increased intraocular pressure; glaucoma; prostatic hypertrophy; diabetes mellitus; thyroid disease; use in patients with renal or hepatic impairment; avoid use with MAOIs or within 14 days of stopping MAOIs; risk of cardiovascular events including stroke and arrhythmias.
["Hypersensitivity to loratadine or any component","Lactation (use with caution)"]
Hypersensitivity to loratadine, pseudoephedrine, or any component; narrow-angle glaucoma; severe hypertension; severe coronary artery disease; concurrent use or recent use of MAOIs (within 14 days); urinary retention; patients with severe hepatic impairment.
Data Pending Review
Data Pending Review
No significant food interactions reported. Avoid concomitant use with alcohol as it may increase risk of drowsiness. Grapefruit juice does not significantly affect loratadine metabolism.
Avoid concurrent consumption of alcohol or caffeine-containing beverages (coffee, tea, cola) as they may exacerbate stimulant effects. Taking with food may reduce gastrointestinal irritation. Avoid high-tyramine foods (aged cheese, cured meats) if also taking MAOIs (contraindicated due to hypertensive crisis risk).
Loratadine (Claritin Reditabs) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. First trimester: In a large prospective study with 681 pregnant women exposed to loratadine, no increased risk of major congenital malformations was observed compared to unexposed controls. Second and third trimesters: Limited data, but no evidence of fetotoxicity or adverse neonatal outcomes. Overall, the risk is considered low, but use only if clearly needed.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimester: Risk of premature labor, low birth weight, and neonatal withdrawal with chronic high-dose decongestant use.
Loratadine is excreted into human breast milk. The calculated milk/plasma (M/P) ratio for loratadine and its active metabolite descarboethoxyloratadine is approximately 1.2 and 0.9, respectively. The relative infant dose (RID) is estimated to be 0.4-1.1% of the maternal weight-adjusted dose, which is low and unlikely to cause adverse effects in infants. However, due to long half-life (12-15 hours), use caution; a shorter-acting antihistamine may be preferred for breastfeeding women.
Loratadine (antihistamine) and pseudoephedrine (decongestant) both excreted in breast milk. M/P ratio for loratadine is approximately 1.1; pseudoephedrine M/P ratio is approximately 2.6. Potential for irritability and decreased milk supply due to pseudoephedrine. Use with caution, preferably immediate-release loratadine alone.
No pharmacokinetic studies specifically in pregnant women have shown significant changes in loratadine absorption, distribution, metabolism, or excretion that require dose adjustment. However, physiological changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may theoretically alter drug levels, but clinical data do not support need for dose modification. Standard adult dosing (10 mg once daily) is appropriate if used.
No standard dose adjustments for pregnancy. Pharmacokinetic changes (increased renal blood flow, decreased plasma protein binding) may alter drug clearance but no specific dose recommendations due to lack of data. Use lowest effective dose for shortest duration.
Category C
Category C
Claritin Reditabs (loratadine) are orally disintegrating tablets that rapidly dissolve on the tongue, making them ideal for patients with swallowing difficulties. Onset of action occurs within 1-3 hours, with peak effect at 8-12 hours. Avoid use in severe hepatic impairment; consider dose adjustment for hepatic or renal impairment.
CLARITIN-D combines loratadine (antihistamine) and pseudoephedrine (decongestant). Use with caution in hypertension, hyperthyroidism, and prostate hypertrophy. Avoid in severe coronary artery disease. Monitor for insomnia and nervousness. Onset of action within 1-3 hours, duration 12 hours. Extended-release formulation must not be crushed or chewed.
Place the tablet on the tongue; it will dissolve rapidly without water.Do not chew or swallow the tablet whole.Use as directed for allergy symptoms; do not exceed 1 tablet per day.May cause drowsiness in some patients; avoid driving until you know how you react.Store in a dry place; do not remove from blister pack until ready to use.
Take exactly as directed; do not exceed 2 tablets in 24 hours.Swallow whole; do not crush or chew extended-release tablets.Avoid alcohol; may increase drowsiness or dizziness.Contact your doctor if symptoms persist beyond 7 days or with fever.Do not use with other decongestants or antihistamines without consulting a physician.May cause insomnia; take last dose at least 4-6 hours before bedtime.Inform your doctor if you have high blood pressure, heart disease, or prostate issues.